Pfizer registers Q4FY21net profit at Rs 100 Cr
Revenue from operations for the year ended March 31, 2021 is ?2,239 crore
Revenue from operations for the year ended March 31, 2021 is ?2,239 crore
The antibody cocktail is to be administered for the treatment of mild to moderate COVID-19
Drop in revenue in the fourth quarter is normal as China is shut down for most of the quarter due to the Chinese New Year holiday
This test is designed for the qualitative detection of nucleic acid from SARS-CoV-2 in the upper and lower respiratory specimens from individuals suspected of COVID-19
The outlook for the US business remains good as respiratory pipeline (gAbraxane, gAdvair, gDulera) adds medium-term growth visibility.
Number of approved manufacturing sites of Remdesivir in the country has increased from 22 sites to 60
Natco has withdrawn its application filed with the Indian Patent Office, seeking Compulsory License against Lilly for Baricitinib for Covid-19 in India
Dr. Reddy's has the rights to distribute 250mn doses in India
A total quantum of more than 4.39 crore doses was also available for direct procurement by the states as well as private hospitals in the month of May 2021
Proactively engaging with foreign vaccine manufacturers like Moderna, Pfizer etc., to apply for Emergency Use Authorization in India so that these vaccines can be easily imported and made available in India
Subscribe To Our Newsletter & Stay Updated